ARTICLE | Finance
Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri
Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri
May 20, 2019 6:08 AM UTC
Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri.
On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million) seed round in Rinri Therapeutics Ltd. with UCB Ventures and participation by BioCity...